List of Excipients in Branded Drug XACIATO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Organon LLC	XACIATO	clindamycin phosphate	78206-189	BENZYL ALCOHOL
Organon LLC	XACIATO	clindamycin phosphate	78206-189	CITRIC ACID MONOHYDRATE
Organon LLC	XACIATO	clindamycin phosphate	78206-189	POLOXAMER 407

XACIATO Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

XACIATO is a single-dose, 2% clindamycin phosphate vaginal gel approved by the FDA for bacterial vaginosis in adult women and pediatric patients aged 12 years and older. Its commercial differentiation depends on local delivery, single-dose convenience, vaginal retention, and a formulation that avoids the adherence problems associated with multi-day vaginal therapy. Excipient innovation can support lifecycle management, generic differentiation, regional expansion, and improved contraceptive compatibility.[1]

What is XACIATO and how does its formulation work?

XACIATO contains clindamycin phosphate equivalent to 100 mg of clindamycin in a 5-gram intravaginal dose. The product is administered once using a prefilled vaginal applicator.[1]

Product attribute	XACIATO profile
Active ingredient	Clindamycin phosphate
Strength	2% vaginal gel
Dose	5 g gel, equivalent to 100 mg clindamycin
Administration	Intravaginal
Treatment schedule	Single dose
Indication	Bacterial vaginosis
Regulatory pathway	FDA-approved NDA
Original applicant	Daré Bioscience
Commercial partner	Organon in the United States
Product category	Small-molecule vaginal anti-infective
Biosimilar pathway	Not applicable

XACIATO uses local vaginal administration to achieve antibiotic exposure at the infection site while limiting the need for repeated dosing. The formulation must remain spreadable during administration, resist rapid leakage, maintain drug uniformity, and remain compatible with vaginal tissue.

The product label warns that the mineral oil component can weaken latex condoms and diaphragms during treatment and for seven days after treatment.[1] That warning is a material commercial constraint and creates a defined opportunity for excipient redesign.

What excipients are important in XACIATO?

The excipient strategy has four functional objectives: gel structure, vaginal residence, chemical stability, and patient-use performance.

Gel-forming and rheology agents

The gel matrix controls:

• Applicator extrusion force
• Spread across the vaginal epithelium
• Resistance to leakage
• Drug suspension or dissolution
• Residence time
• Dose uniformity

A successful substitute must reproduce the product's rheological profile over the relevant temperature range. A gel that is too viscous may increase applicator force and reduce dose delivery. A gel that is too fluid may leak rapidly and lower local exposure.

Candidate excipient classes include:

Excipient class	Strategic purpose	Main development issue
Cellulose derivatives	Viscosity and film formation	Drug release and microbial compatibility
Carbomers	High viscosity at low concentration	Neutralization, irritation, and ionic sensitivity
Poloxamers	Thermoresponsive gel behavior	Complex temperature-dependent release
Polycarbophil	Mucoadhesion and retention	Potentially excessive residence or irritation
Gellan gum	Ion-sensitive gel formation	Vaginal electrolyte sensitivity
Hydroxypropyl methylcellulose	Viscosity and coating	May require higher concentration
Thiolated polymers	Strong mucoadhesion	Regulatory and impurity burden

The commercial opportunity is strongest where an excipient can improve retention without increasing systemic clindamycin exposure or causing local irritation.

Mucoadhesive excipients

Mucoadhesion may reduce post-dose leakage and improve contact time. Potential platforms include polycarbophil, carbomer derivatives, chitosan, thiolated polymers, and selected cellulose polymers.

The regulatory burden is higher when the excipient is novel for vaginal use. A reformulation using an established excipient at a known concentration has a clearer FDA pathway than one using a new mucoadhesive polymer with limited reproductive or chronic mucosal safety data.

A practical development target is moderate adhesion rather than maximum adhesion. Excessive adhesion may interfere with natural clearance, increase patient discomfort, or produce inconsistent drug release.

Solubilizers and cosolvents

Clindamycin phosphate is water soluble, but the finished product must remain chemically stable in a vaginal environment and throughout shelf life. Propylene glycol and related cosolvents can influence:

• Drug solubility
• Osmolality
• Preservative efficacy
• Vaginal irritation
• Drying or stinging sensation
• Container compatibility

A reformulation should avoid unnecessary cosolvent loading. High osmolality can damage epithelial cells and may affect tolerability. Osmolality, pH, buffering capacity, and preservative concentration should be evaluated together rather than optimized independently.

Mineral oil and lipid components

Mineral oil provides emollient and formulation benefits but creates a significant use limitation because of latex barrier-device weakening. Removing mineral oil would support a commercially meaningful claim:

• Compatible with latex condoms and diaphragms
• Reduced post-treatment contraception restriction
• Improved suitability for patients relying on barrier contraception
• Potential differentiation from the reference product

A lipid-free or silicone-based system could be evaluated, although silicone excipients introduce their own compatibility, labeling, and manufacturing considerations. Any replacement must preserve drug release and applicator performance.

What formulation patents protect XACIATO?

XACIATO's principal intellectual-property value is expected to reside in formulation and vaginal-delivery claims rather than in the clindamycin molecule itself. Clindamycin is an established antibiotic, and composition-of-matter protection for the active ingredient is not a meaningful barrier to generic entry.

Relevant claim categories may include:

1. Clindamycin phosphate vaginal gel compositions.
2. Specific polymer, solvent, and oil combinations.
3. Concentration ranges and rheological parameters.
4. Single-dose vaginal delivery.
5. Treatment of bacterial vaginosis using the formulation.
6. Product-by-process or manufacturing controls.
7. Applicator and unit-dose packaging configurations.

Patent strength depends on claim breadth, written-description support, prosecution history, and whether a generic product can alter one or more excipients while maintaining the same active ingredient, strength, route, and dosage form.

A narrow formulation patent can still delay a generic if the reference composition is easy to copy. Its weakness is that a generic applicant may substitute a different viscosity agent, remove mineral oil, modify the preservative system, or use a different applicator.

How strong is the XACIATO patent estate?

The estate is stronger against direct copies than against engineered alternatives. The active ingredient provides little protection. The commercial barrier is the combination of:

• Local vaginal delivery
• Single-dose administration
• Gel performance
• Applicator design
• Clinical and regulatory data
• Formulation patents
• Trademark and market recognition

A generic applicant seeking approval through an ANDA would generally need to address Orange Book-listed patents through certification. A Paragraph IV certification could trigger patent litigation under the Hatch-Waxman framework.[2]

The most credible design-around pathway is a nonidentical vaginal gel with:

• No mineral oil
• A different gelling or mucoadhesive polymer
• A comparable clindamycin phosphate concentration
• The same or an equivalent therapeutic indication
• A redesigned applicator

When does XACIATO lose exclusivity?

XACIATO received FDA approval in December 2021. Its five-year new chemical entity exclusivity period therefore ran until December 2026, subject to FDA Orange Book treatment and any applicable patent or pediatric exclusivity.[3]

Exclusivity or protection	Timing
FDA approval	December 2021
Five-year NCE exclusivity	Generally through December 2026
Patent protection	Depends on listed patents, terminal disclaimers, PTA, and litigation outcomes
Generic filing opportunity	ANDA filing may occur before exclusivity expiration if a Paragraph IV certification is used
Earliest commercial generic entry	Controlled by exclusivity, patent outcomes, settlements, and regulatory approval

The exact loss-of-exclusivity date cannot be inferred from FDA exclusivity alone. Patent expiration dates, pediatric exclusivity, patent-term adjustment, and settlement provisions can change the commercial entry date.

What is the Orange Book status of XACIATO?

XACIATO is an FDA-approved NDA product. The FDA Orange Book is the controlling source for current listed patents, exclusivity codes, and therapeutic-equivalence information.[3]

The strategic Orange Book issues are:

• Whether formulation patents are listed against NDA 215790.
• Whether any method-of-use patents remain listed.
• Whether patent expiration dates extend beyond December 2026.
• Whether a generic applicant can certify Paragraph III or Paragraph IV.
• Whether the reference product has an RLD designation suitable for ANDA reliance.

For market-entry analysis, the Orange Book should be reviewed together with the FDA patent-listing database, USPTO patent records, and federal court dockets. Patent-listing status is more relevant than the existence of a broader patent portfolio because only properly listed patents create the standard Orange Book certification framework.

Which companies are challenging XACIATO?

No widely reported, publicly adjudicated Paragraph IV litigation against XACIATO is established in the core FDA and company disclosures reviewed for this analysis. The absence of public litigation does not eliminate future challenge risk.

Potential challengers include:

• Generic vaginal anti-infective manufacturers.
• Companies with clindamycin oral, topical, or vaginal manufacturing capability.
• Contract development and manufacturing organizations with semisolid dosage expertise.
• Specialty generic companies focused on difficult-to-formulate vaginal products.

The most likely challenge would involve a formulation design-around rather than an attack on clindamycin's active ingredient.

What generic launch risks exist for XACIATO?

Scenario 1: Direct-copy ANDA

A direct-copy product would have the lowest development risk but the highest patent exposure. It would need to match the reference product closely and address listed formulation patents.

Scenario 2: Formulation design-around

A design-around could replace mineral oil, modify the gel matrix, and use a different unit-dose applicator. This approach may reduce patent risk but increase regulatory and clinical comparability requirements.

Scenario 3: 505(b)(2) product

A 505(b)(2) applicant could pursue a modified vaginal formulation, a different dosing profile, or a differentiated delivery system while relying partly on existing findings for clindamycin. This pathway may support improved barrier-device compatibility or reduced leakage, but it may require additional clinical or pharmacokinetic evidence.[4]

Generic strategy	Patent risk	Development cost	Commercial differentiation
Direct-copy ANDA	High	Lower	Low
Excipient design-around ANDA	Moderate	Moderate	Moderate
505(b)(2) reformulation	Lower relative to direct copy	Higher	High
New non-antibiotic BV product	Low against XACIATO patents	High	High

What excipient opportunities could support XACIATO lifecycle management?

Latex-compatible reformulation

The clearest opportunity is a mineral-oil-free product. A reformulation could target compatibility with latex condoms and diaphragms, provided the replacement system maintains stability, release, and clinical performance.

Longer-retention gel

A bioadhesive gel could reduce leakage and improve perceived efficacy. The development program would need to assess vaginal residence, local tolerability, epithelial effects, and clindamycin exposure.

Lower-osmolality formulation

A lower-osmolality gel may improve comfort and reduce epithelial stress. The product would need a balanced preservative and microbial-control system.

Preservative-free unit dose

Because XACIATO is supplied in a single-use applicator, a preservative-free presentation may be technically feasible. Removing preservatives could improve tolerability, but microbial control would shift toward manufacturing controls, container closure, and package integrity.

Thermoresponsive delivery

A low-viscosity product during administration that thickens at vaginal temperature could improve applicator usability and retention. Poloxamer-based systems are candidates, but phase behavior and drug release must remain consistent across storage conditions.

Combination vaginal therapy

A formulation platform could combine clindamycin with an antifungal, probiotic-supportive component, or agent directed at recurrent bacterial vaginosis. Combination products face additional compatibility, clinical, and regulatory requirements. They may also create new patentable composition and method claims.

Sustainable packaging

A prefilled applicator using lower-material packaging, recyclable components, or lower-carbon manufacturing could support institutional procurement and specialty-pharmacy positioning. Packaging changes would need extractables, leachables, dose-delivery, and stability validation.

How does XACIATO compare with competing bacterial-vaginosis products?

Product	Active ingredient	Dosing pattern	Formulation issue	Excipient opportunity
XACIATO	Clindamycin phosphate	Single dose	Mineral-oil latex warning; gel leakage and retention	Latex-compatible and lower-leakage reformulation
Clindesse	Clindamycin phosphate	Single dose	Vaginal cream platform	Gel versus cream performance
Cleocin vaginal products	Clindamycin phosphate	Multi-day or product-dependent	Repeated administration	Single-dose delivery differentiation
Metronidazole vaginal gel	Metronidazole	Multi-day	Repeated dosing and leakage	Long-retention or single-dose systems
Secnidazole oral granules	Secnidazole	Single oral dose	Systemic exposure and gastrointestinal tolerability	Local vaginal delivery alternatives

XACIATO's main commercial advantage is single-dose local therapy. Its main formulation disadvantage is the latex barrier-device warning. An excipient strategy that preserves single-dose administration while removing the warning would address a direct competitive weakness.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can pursue five practical opportunities.

1. Replacement polymers: Supply vaginally acceptable rheology modifiers with low irritation potential and strong regulatory histories.
2. Mucoadhesive systems: Develop proprietary polymer blends that extend residence without impeding natural clearance.
3. Lipid-free delivery platforms: Replace mineral oil with compatible non-lipid systems.
4. Preservative-free unit-dose systems: Pair low-bioburden manufacturing with optimized container closure.
5. Co-development partnerships: Offer formulation, scale-up, analytical, and regulatory support to generic or 505(b)(2) applicants.

The highest-value opportunity is a platform that combines latex compatibility, low osmolality, acceptable applicator force, and comparable local drug release. A single excipient substitution is less commercially defensible than a validated formulation system with process know-how and performance specifications.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers include:

• Uniform filling of a semisolid vaginal gel.
• Control of viscosity across batches.
• Prevention of air entrapment in prefilled applicators.
• Compatibility between the gel and applicator materials.
• Sterility or microbial-limit control, depending on the product design.
• Stability under temperature excursions.
• Consistent clindamycin phosphate assay and degradation profile.

Potentially protectable manufacturing innovations include polymer hydration order, neutralization sequence, deaeration, filling temperature, in-line viscosity control, and container-closure methods. These process claims may be valuable when composition claims are narrow or vulnerable to design-around.

What is the revenue exposure for XACIATO?

XACIATO's revenue exposure is concentrated in the U.S. bacterial-vaginosis market and depends on three factors:

• Conversion from multi-day to single-dose treatment.
• Prescriber acceptance of clindamycin despite resistance and recurrence concerns.
• Organon's commercialization scale and payer access.

Public company disclosures do not establish a sufficiently reliable standalone XACIATO revenue series for valuation. Commercial upside is more readily assessed through prescription volume, net price, payer coverage, refill or retreatment behavior, and the proportion of bacterial-vaginosis prescriptions captured from metronidazole and older clindamycin products.[5]

The product's single-dose format supports premium pricing, but the latex warning may reduce use among patients who rely on condoms or diaphragms. A latex-compatible reformulation could improve addressable demand without changing the active ingredient.

Key Takeaways

• XACIATO is a single-dose 2% clindamycin phosphate vaginal gel approved in December 2021.
• Its strongest commercial differentiator is single-dose local therapy.
• Mineral oil creates a clinically relevant latex condom and diaphragm limitation.
• The best excipient opportunity is a mineral-oil-free, lower-osmolality, retention-optimized gel.
• The active ingredient offers limited patent protection because clindamycin is established.
• Formulation, delivery-device, manufacturing, and method-of-use claims are more important than composition-of-matter claims.
• Generic risk is likely to arise through a formulation design-around or 505(b)(2) product.
• No biosimilar pathway applies because XACIATO is a small-molecule drug.
• Excipient suppliers with vaginal safety data and scale-up capability have the strongest commercial positioning.

FAQs

Can XACIATO be reformulated without clindamycin phosphate?

Yes. A lifecycle product could retain clindamycin phosphate while changing the polymer, oil phase, preservative system, buffering system, or applicator. The reformulation would need to establish pharmaceutical equivalence or an appropriate 505(b)(2) basis.

Would removing mineral oil eliminate the latex warning?

It could remove the specific mineral-oil basis for the warning, but the final labeling would depend on the complete formulation, compatibility testing, and FDA review.

Is a mucoadhesive XACIATO generic likely to require new clinical trials?

The requirement would depend on the degree of formulation change, the ANDA suitability, comparative dissolution or release data, local exposure, and FDA determination. A materially different mucoadhesive system is more likely to require evidence beyond routine pharmaceutical equivalence.

Can a generic manufacturer patent a new XACIATO excipient system?

Yes. A generic or specialty pharmaceutical company could seek patents covering a nonidentical composition, excipient concentration range, manufacturing process, applicator, or improved clinical property.

Does XACIATO have biosimilar competition?

No. XACIATO contains clindamycin phosphate, a small molecule. Competition would proceed through generic or 505(b)(2) pathways rather than biosimilar approval.

References

1. U.S. Food and Drug Administration. (2021). XACIATO (clindamycin phosphate) vaginal gel, 2% prescribing information.
2. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
4. U.S. Food and Drug Administration. (2019). Applications covered by Section 505(b)(2).
5. Daré Bioscience, Inc. (2024). Annual report on Form 10-K.